Open AccessA systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine
Author(s) -
Edoardo Marrani,
Sarah AbuRumeileh,
Maria Vincenza Mastrolia,
Ilaria Maccora,
Ilaria Pagnini,
Gabriele Simonini
Publication year - 2022
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/ltrj4l
Subject(s) - medicine , adalimumab , juvenile dermatomyositis , infliximab , etanercept , rituximab , tocilizumab , cochrane library , medline , polymyositis , myositis , dermatomyositis , pediatrics , dermatology , meta analysis , tumor necrosis factor alpha , lymphoma , disease , political science , law
Juvenile idiopathic inflammatory myopathies (JIIMs) are a heterogeneous group of systemic autoimmune diseases. Juvenile dermatomyositis (JDM) is the predominant form of JIIMs, and is a rare, chronic autoimmune illness characterised by symmetric, proximal muscle damages and involvement of the skin. In the last two decades, the use of monoclonal antibodies has also been expanded to JIIMs; however, there is limited evidence on use of these treatments. We assessed the efficacy/effectiveness and safety of biologic agents in JIIMs.